Guide · Updated March 2026

Zepbound vs Mounjaro: Same Drug, Different Price

Zepbound and Mounjaro both contain tirzepatide, a dual GIP/GLP-1 receptor agonist made by Eli Lilly. Same molecule, same doses (2.5 to 15 mg), same injection pen. The difference is the FDA label and what you pay. With insurance for diabetes, Mounjaro can cost $25/month. Without insurance, Zepbound through LillyDirect runs $349-$499/month. Your diagnosis determines your price.

The Zepbound vs Mounjaro difference confuses almost everyone I talk to about GLP-1 medications. People assume they are different drugs. They are not. Tirzepatide is tirzepatide. The active ingredient, the pen design, the manufacturer, even the dose options are identical. I have been on Mounjaro for over a year and tracked everything with DEXA scans. If my pharmacy switched me to Zepbound at the same dose tomorrow, nothing about the drug entering my body would change.

What would change is my bill.

That price gap is what this guide is about. I will walk through exactly what each version costs in 2026, who qualifies for the cheapest path, and the specific steps to pay the least for the same medication.

Why the Same Drug Has Two Names (and Two Prices)

Eli Lilly filed two separate FDA applications for tirzepatide. Mounjaro was approved in May 2022 for type 2 diabetes, based on the SURPASS trials measuring A1C reduction. Zepbound was approved in November 2023 for chronic weight management, based on the SURMOUNT trials measuring body weight loss.

The FDA indication on the label drives everything downstream. Insurance formularies, prior authorization rules, copay tiers, and savings programs all flow from whether the drug is classified as a diabetes medication or a weight management medication. In the US healthcare system, those two categories live in completely different worlds.

Diabetes drugs have been on formularies for decades. Insurers expect to cover them. Weight loss drugs are still treated as optional by most plans. That single distinction creates a pricing gap of hundreds of dollars per month for the exact same molecule.

The Real Cost Breakdown (March 2026)

Cost Scenario	Mounjaro	Zepbound
List price (no insurance)	~$1,023/mo	~$1,086/mo
Commercial insurance (diabetes)	$25-$150/mo	Usually not covered for diabetes
Commercial insurance (weight loss)	Off-label, coverage varies	$25-$150/mo if plan covers obesity meds
Lilly savings card	As low as $25/mo (with eligible insurance)	Not applicable
LillyDirect self-pay (no insurance)	Not available through LillyDirect	$349/mo (2.5mg), $499/mo (5mg+)
Compounded tirzepatide	$149-$399/mo	$149-$399/mo
Medicare	Covered for T2D only	Not covered

The numbers tell a clear story. If you have type 2 diabetes and commercial insurance, Mounjaro at $25/month is the cheapest way to get tirzepatide in the country. If you are paying out of pocket for weight loss, Zepbound through LillyDirect at $349-$499/month is the branded option, though compounded tirzepatide undercuts it.

For a broader look at all GLP-1 pricing options, including semaglutide, see our complete cost breakdown.

The Clinical Data Is Identical (Because It Is the Same Drug)

I want to be direct about this: there is no clinical reason to prefer one over the other. The SURMOUNT-1 trial (NEJM, July 2022) tested tirzepatide in 2,539 adults with obesity and no diabetes. Results at 72 weeks:

5 mg: 16.0% body weight lost (35 lbs)
10 mg: 21.4% body weight lost (49 lbs)
15 mg: 22.5% body weight lost (52 lbs)
Placebo: 2.4%

At the highest dose, 57% of participants lost 20% or more of their body weight. Those numbers supported Zepbound’s FDA approval, but the molecule producing those results is the same one in every Mounjaro pen.

The SURMOUNT-5 trial (NEJM, May 2025) compared tirzepatide head-to-head against semaglutide (the molecule in Ozempic and Wegovy). Tirzepatide produced 20.2% weight loss vs 13.7% for semaglutide over 72 weeks. That is 47% more weight loss, with fewer GI-related dropouts (2.7% vs 5.6%). Whether the pen said Mounjaro or Zepbound, the advantage held.

On my own experience at 15 mg: my DEXA showed a 33.9% fat mass decrease with only 10.9% lean mass decrease. The lean-to-fat loss ratio on tirzepatide is better than what the semaglutide trials showed, where lean mass made up 39-45% of total weight lost (Neeland 2024, Diabetes Obesity Metabolism).

Side Effects: Also Identical

Same molecule, same side effects. From the SURMOUNT-1 data:

Nausea: 24.6-31.0% (vs 9.5% placebo)
Diarrhea: 18.7-23.0% (vs 7.3%)
Constipation: 11.7-17.1% (vs 5.8%)
Vomiting: 8.3-12.2% (vs 1.7%)

Discontinuation due to side effects ranged from 4.3-7.1%, which is actually lower than the semaglutide trials. Most side effects hit during dose escalation and fade after a few weeks at each dose. I covered what helped me manage the nausea in our Mounjaro nausea guide, and we have a full GLP-1 side effects timeline if you want the month-by-month picture.

The point: do not pick between Mounjaro and Zepbound based on side effects. They will be identical.

Insurance: The Only Thing That Actually Matters

This is where the Zepbound vs Mounjaro difference becomes real. Not in the drug itself, but in how insurance companies treat it.

If You Have Type 2 Diabetes

Mounjaro is the clear winner. Most commercial plans and Medicare Part D formularies cover it for diabetes. Your prescriber submits a prior authorization showing your A1C level, and approval rates are high. With Lilly’s savings card on top of covered insurance, your copay can drop to $25/month.

That is $25 for the same drug that costs $1,086 at list price.

If You Want Weight Loss Without Diabetes

This is harder. Zepbound is the on-label choice for weight management, but many employer plans still exclude anti-obesity medications entirely. Coverage is growing (some large employers and state programs have added it), but it is far from universal.

If your plan does cover obesity medications, Zepbound works the same way as any covered drug: prior authorization, possible step therapy, then a copay in the $25-$150 range.

If your plan does not cover it, you have three options:

LillyDirect self-pay: $349/month for the 2.5 mg starter dose, $499/month for 5 mg and above. No insurance needed. This is Lilly’s direct-to-patient program.
Compounded tirzepatide: $149-$399/month through telehealth providers. Same active molecule from compounding pharmacies. See our compounded vs brand-name comparison for the tradeoffs.
Ask about off-label Mounjaro: If you have prediabetes, metabolic syndrome, or elevated fasting glucose, your doctor may be able to prescribe Mounjaro with a metabolic indication. This is a legitimate clinical decision, not a loophole, but coverage is not guaranteed.

For step-by-step help figuring out your insurance situation, our GLP-1 insurance coverage guide breaks down the prior authorization process.

Compare GLP-1 providers

Browse Provider Directory →

Medicare Patients: Limited Options

Medicare Part D covers Mounjaro only for type 2 diabetes. It does not cover Zepbound or any GLP-1 for weight management. Legislative proposals to change this have been circulating since 2024, but nothing has passed as of March 2026.

If you are on Medicare and want tirzepatide for weight loss, your options are LillyDirect self-pay ($349-$499/mo) or compounded tirzepatide through a telehealth provider. Neither involves insurance. Both are cash-pay paths worth evaluating based on your budget.

The Compounded Third Option

If both brand names are too expensive, compounded tirzepatide costs $149-$399/month depending on the provider and dose. This is the same active molecule produced by US-licensed compounding pharmacies.

The regulatory situation for compounded GLP-1s has shifted. The FDA resolved the tirzepatide shortage in October 2025, which narrowed the legal basis for mass compounding under 503B facilities. Patient-specific compounding under 503A may continue in some form. Check our compounded semaglutide legal guide for the latest status (the legal framework applies to tirzepatide as well).

Telehealth providers like Ro, Hims, and MEDVi offer compounded tirzepatide programs. Quality varies by pharmacy, so look for providers using 503B outsourcing facilities (FDA-inspected) rather than 503A pharmacies.

How to Pay the Least for Tirzepatide in 2026

Here is a decision tree based on your situation:

Step 1: Check your insurance. Do you have commercial insurance? Does it cover Mounjaro (for diabetes) or Zepbound (for weight management)?

Step 2: Talk to your prescriber. If you have type 2 diabetes or prediabetes, Mounjaro with a savings card ($25/mo) is almost certainly your cheapest path. If you do not have diabetes, ask whether your plan covers Zepbound.

Step 3: If insurance says no. Compare LillyDirect Zepbound ($349-$499/mo) vs compounded tirzepatide ($149-$399/mo) vs switching to a semaglutide option that might be cheaper or better covered.

Step 4: Use savings programs. Lilly’s savings card can stack on top of insurance for Mounjaro. The copay card and patient assistance guide has the application links and eligibility details.

For a full pricing comparison across all GLP-1 options (not just tirzepatide), see our cheapest GLP-1 online guide.

Can You Switch Between Mounjaro and Zepbound?

Yes, and it is simple. Your prescriber writes a new prescription for the other brand at the same dose. No titration period. No dose adjustment. The pharmacy dispenses whichever one is on the script. The most common reasons to switch:

Your insurance coverage changes
One brand has a supply shortage
You move from a diabetes indication to a weight management indication (or vice versa)
A different savings program becomes available

One thing to know: pharmacies cannot substitute one for the other on their own. Even though the molecule is identical, they have different NDC codes. Your prescriber needs to write the specific brand.

Bottom Line

Zepbound and Mounjaro are the same drug at different prices. Your diagnosis and insurance determine which one you can access and what you pay. If you have type 2 diabetes and commercial insurance, Mounjaro at $25/month is the best deal in the GLP-1 market. If you are paying cash for weight loss, compare LillyDirect Zepbound ($349-$499/mo) against compounded tirzepatide ($149-$399/mo) and pick based on your budget and comfort level with compounding pharmacies. Use our provider directory to compare programs that prescribe tirzepatide and find the best fit for your situation.

Frequently Asked Questions

Is there any medical difference between Zepbound and Mounjaro?

No. Both contain tirzepatide made by Eli Lilly in the same doses (2.5 to 15 mg) using the same injection pen. The only difference is the FDA indication on the label: Mounjaro for type 2 diabetes, Zepbound for weight management. The drug itself is identical.

Why is Mounjaro cheaper than Zepbound for some people?

Insurance coverage. Diabetes medications are covered by most commercial plans and Medicare Part D. Weight management drugs face more exclusions. If your insurance covers Mounjaro for diabetes and you stack Lilly’s savings card, the copay can be as low as $25/month. Zepbound often requires cash payment through LillyDirect at $349-$499/month.

Can my doctor prescribe Mounjaro for weight loss?

Technically yes, as an off-label prescription. Some insurers cover off-label Mounjaro for weight management, but many do not. If you have prediabetes or metabolic syndrome, your doctor may prescribe Mounjaro with a metabolic indication. If you have no metabolic condition, Zepbound is the on-label weight loss option.

Is compounded tirzepatide the same as Mounjaro and Zepbound?

Compounded tirzepatide uses the same active ingredient but is produced by compounding pharmacies, not Eli Lilly. The raw molecule is the same, but the final product is not FDA-approved as a finished drug. It costs $149-$399/month compared to $1,023-$1,086 at brand list price.

Can I use my FSA or HSA to pay for Zepbound or Mounjaro?

Yes, both are eligible expenses under FSA and HSA plans when prescribed by a licensed provider. This applies to brand-name and compounded versions. See our FSA/HSA guide for details on documentation and reimbursement.

This article is for informational purposes only and does not constitute medical advice. Pricing information is approximate and based on publicly available data as of March 2026. Actual costs may vary. Always consult with a qualified healthcare provider before starting any medication.

Related

Guides:

Provider Reviews: Ro · Hims · MEDVi · Found · Calibrate

Compare: All Providers · Best GLP-1 Programs · All Guides